Alaunos Therapeutics, Inc. (TCRT) Net margin 2016–2025
Alaunos Therapeutics, Inc. (TCRT) net profit margin by fiscal year — reported net income divided by reported revenue.
-83520.0%FY2025 · since FY2016: -2409.2% → -83520.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -83520.0% | -36730.0 pp |
| FY2024 | -46790.0% | +46790.0 pp |
| FY2023 | -93580.0% | -92288.8 pp |
| FY2022 | -1291.2% | +18495.4 pp |
| FY2021 | -19786.7% | — |
| FY2018 | -36381.5% | -35531.2 pp |
| FY2017 | -850.3% | +1559.0 pp |
| FY2016 | -2409.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRT financial trends
TCRT RevenueTCRT Net incomeTCRT Gross profitTCRT Gross marginTCRT Operating incomeTCRT Operating marginTCRT Operating cash flowTCRT Free cash flowTCRT Capital expendituresTCRT Return on equityTCRT Stock buybacksTCRT Dividends paidTCRT Total assetsTCRT Total liabilitiesTCRT Shareholders’ equityTCRT overview →